Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) METOCLOPRAMIDE HYDROCHLORIDE RENAUDIN 10 mg/2 mL, solution for injection in ampoule
Section 19A approved medicine
(Approval lapsed) METOCLOPRAMIDE HYDROCHLORIDE RENAUDIN 10 mg/2 mL, solution for injection in ampoule
Section 19A approval holder
Link Medical Products Pty Ltd ABN 73 010 971 516
Phone
1800 181 060
Approved until
Status
Expired
Medicines in short supply/unavailable
Pfizer (Perth) metoclopramide hydrochloride monohydrate 10mg/2mL injection BP ampoule - ARTG 11364
MAXOLON metoclopramide hydrochloride monohydrate 10mg/2mL injection ampoule - ARTG 40204
MAXOLON metoclopramide hydrochloride monohydrate 10mg/2mL injection ampoule - ARTG 40204
Indication(s)
Adults (20 years and over):
- Relief of nausea and vomiting associated with migraine, cancer therapy (chemotherapy or radiation), malignant disease, labour, infectious disease and uraemia
- Control of post-operative vomiting
- Metoclopramide is of little benefit for the prevention or treatment of motion sickness.
Young Adults (under 20) and Children (over 1 year of age):
Metoclopramide should only be used as second line therapy because of the risk of adverse effects:
- Severe intractable vomiting of known cause
- Vomiting associated with radiation therapy or intolerance to cytotoxic drugs